We have explored in detail the relationship between Ab evolution and the pharmacokinetics and pharmacodynamics associated with pegloticase therapy, as well as the effect on tolerability.
Furthermore, increasing the dose of epirubicin from 50 to 75 mg m−2 appears to improve the response rates in patients with advanced breast cancer who are treated with the FEC regimen, with no significant effect on tolerability (French Epirubicin Study Group, 1991; Ormrod et al, 1999).
The LEAD study results also suggested that such patients are likely to maintain control of IGF1, GH and symptoms for up to at least 1 year without adverse effects on tolerability or HRQoL.
Perhaps most importantly, we analyzed the effects of tolerability on the number of measurements one can expect to obtain from studies of participants in which ambulatory BP monitoring is used.
It should be noted, however, that medications used in the older patient group and the younger patient group were not significantly different with respect to the effect on antiretroviral tolerability and response.
Recent studies in ovarian or lung cancer patients receiving cisplatin-based chemotherapy have demonstrated that higher Hb levels will exert a positive effect on the patients' tolerability of chemotherapy (Manegold, 1998; Obermair et al, 1998; Pivot et al, 2000).
Exploratory post hoc end points included analyses of the effect on efficacy and tolerability of age (70 75 years, >75 years), performance status (ECOG performance status 0, 1), extent of disease (1, 2, ⩾3 organs with metastases) and baseline creatinine clearance (>50 ml min−1, ⩽50 ml min−1).
We believe this missing information was crucial, as side effects had a bearing on tolerability of the interventions.
Such studies should assess safety and tolerability, effect on downstream hormones such as estradiol, optimal dosing, and impact on mood.
These drug interactions may lead to suboptimal levels of antiretroviral drug and emergence of resistance, or may lead to supraoptimal levels with a negative impact on tolerability and side effects.
The combination regimen was well tolerated with no adverse effects on the safety, tolerability and pharmacokinetics of either agent.
